Cerogenix Ltd, formed in September 2005 from King's College London, is currently developing novel therapeutics for neurological diseases such as Alzheimer's and Parkinson's disease; a multi billion-dollar market opportunity.

Near term developments will focus on a diagnostic tool for the early detection of neurodegenerative diseases, with the objective of enabling clinicians to identify the correct treatment for patients at an earlier stage than is currently possible.


For further information please e-mail: enquiries@cerogenix.com